LEXEO THERAPEUTICS INC. COMMON STOCK
NASDAQ: LXEO (Lexeo Therapeutics, Inc.)
Last update: 3 hours ago11.50
-0.29 (-2.46%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Lexeo Therapeutics, Inc. | Bearish | - |
Stockmoo Score
|
Lexeo Therapeutics Inc is a a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Its pipeline consists of candidates targeting patient populations that place significant burden on society and are most amenable to their genetic medicine approach. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need which is their only business segment. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| D1 Capital Partners L.P. | 31 Mar 2024 | 2,506,607 |
| Omega Fund Management, Llc | 31 Mar 2024 | 2,355,904 |
| Novo Holdings A/S | 31 Mar 2024 | 1,638,298 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 28.00 (Baird, 143.48%) | Buy |
| Median | 23.00 (100.00%) | |
| Low | 22.00 (HC Wainwright & Co., 91.30%) | Buy |
| Average | 24.33 (111.57%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 14.80 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 16 Jul 2024 | 22.00 (91.30%) | Buy | 12.64 |
| 06 Jun 2024 | 22.00 (91.30%) | Buy | 17.45 | |
| Chardan Capital | 15 Jul 2024 | 23.00 (100.00%) | Buy | 13.01 |
| Baird | 13 Jun 2024 | 28.00 (143.48%) | Buy | 18.76 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 15 Jul 2024 | Announcement | Lexeo Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy |
| 11 Jul 2024 | Announcement | Lexeo Therapeutics Announces Investor Webcast to Report Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy on Monday, July 15, 2024 |
| 08 Jul 2024 | Announcement | Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors |
| 09 May 2024 | Announcement | Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights |
| 07 May 2024 | Announcement | Lexeo Therapeutics to Participate in Upcoming Investor Conferences |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |